Abstract
Kanserler genel olarak çoklu genetik ve epigenetik anormallikler içermekte fakat birkaç anahtar gen sayesinde malign fenotip ve hücresel sağkalımın devamlılığı sağlanmaktadır. PI3K/Akt/mTOR yolağı önemli birçok fizyolojik olaylarda rol alan merkezi bir sinyal akım sistemidir. PI3K/Akt/mTOR yolağı birçok tümör çeşidi tarafından kullanıldığından bu yolağa karşı kullanılan inhibitörlerin geniş bir terapötik etkinliğinin olabileceği düşünülmektedir. Tekli tedavide bu inhibitörlerin hiçbiri ile faz 1 çalışmalarda önemli cevap oranları elde edilememiş olup yüksek dozların kısa sürelerde verilmesi ve değişik yolaklara etkili olabilecek ilaçların kombine edilmesi gibi diğer seçenekler araştırılmaktadır.
Keywords
References
- 1. Timothy A Yap, Michelle D Garrett, Mike I Walton, Florence Raynaud, Johann S de Bono, Paul Workman. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Current opinion in pharmacology, 2008;8:393-412.
- 2. Weinstein IB, Joe AK: Mechanisms of disease: oncogene addiction — a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457.
- 3. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
Abstract
Cancers generally contain multiple genetic and epigenetic abnormalities, but several key genes maintain the malignant phenotype and cellular survival. The PI3K/Akt/mTOR pathway is a central signaling system that plays a role in many important physiological events. Since the PI3K/Akt/mTOR pathway is used by many tumor types, it is thought that inhibitors used against this pathway may have a wide therapeutic efficacy. Significant response rates could not be obtained in phase 1 studies with any of the agents in monotherapy, and other options are being investigated by administering high doses in short periods and combining drugs that may affect different pathways.
References
- 1. Timothy A Yap, Michelle D Garrett, Mike I Walton, Florence Raynaud, Johann S de Bono, Paul Workman. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Current opinion in pharmacology, 2008;8:393-412.
- 2. Weinstein IB, Joe AK: Mechanisms of disease: oncogene addiction — a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457.
- 3. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Review |
| Authors | |
| Publication Date | March 31, 2022 |
| Acceptance Date | January 11, 2022 |
| Published in Issue | Year 2022 Volume: 31 Issue: 1 |
